Search results
Earnings call: Lexicon Pharmaceuticals Q1 2024 financial results and CEO retirement By Investing.com
Investing.com· 4 hours agoLexicon Pharmaceuticals Inc. (NASDAQ:LXRX) reported a net loss of $48.4 million in the first quarter...
Met Gala tickets, which are invite-only, cost $75,000. Here's what that gets attendees.
INSIDER via Yahoo News· 1 hour agoThe Metropolitan Museum of Art reported that this exhibit included about 100 men's and women's...
Lexicon Pharmaceuticals Inc (LXRX) Shares Rise Despite Market Challenges – News Heater
NewsHeater· 13 hours agoThe stock of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) has increased by 2.35 when compared to last closing price of 1.70.Despite this, the company has seen a gain of 10.13% ...
Kim Kardashian's Met Gala looks, ranked from least to most iconic
INSIDER via Yahoo News· 3 hours agoMike Coppola/Getty Images "The Kardashians" star shocked fans by arriving at the 2021 "In America: A...
Met Gala 2024: How to Watch the Red Carpet Livestream
Glamour via Yahoo News· 7 hours agoThe 2021 Met Gala Celebrating In America: A Lexicon Of Fashion - Arrivals Taraji P. Henson in 2021...
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance· 4 days agoLexicon (LXRX) delivered earnings and revenue surprises of -11.11% and 3.09%, respectively, for the...
Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ...
GuruFocus.com via Yahoo Finance· 4 days agoOn May 2, 2024, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) disclosed its financial outcomes for the...
Lexicon Pharmaceuticals, Inc. to Post Q1 2024 Earnings of ($0.13) Per Share, Leerink Partnrs...
ETF DAILY NEWS· 3 days agoLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) – Investment analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for shares of Lexicon< ...
Q1 2024 Lexicon Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 3 days agoParticipants Lisa DeFrancesco; Head, Investor Relations and Strategy; Lexicon Pharmaceuticals Inc Lonnel Coats; Chief Executive Officer, Director; Lexicon
Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to “Sell” by StockNews.com
ETF DAILY NEWS· 6 days agoLexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) was upgraded by equities researchers at StockNews.com to a “sell” rating in a report issued on Wednesday. A number ...
